BACKGROUND: This study sought to determine whether tight glycemic control with a modified glucose-insulin-potassium (GIK) solution in diabetic coronary artery bypass graft (CABG) patients would improve perioperative outcomes. METHODS AND RESULTS: One hundred forty-one diabetic patients undergoing CABG were prospectively randomized to tight glycemic control (serum glucose, 125 to 200 mg/dL) with GIK or standard therapy (serum glucose <250 mg/dL) using intermittent subcutaneous insulin beginning before anesthesia and continuing for 12 hours after surgery. GIK patients had lower serum glucose levels (138+/-4 versus 260+/-6 mg/dL; P<0.0001), a lower incidence of atrial fibrillation (16.6% versus 42%; P=0.0017), and a shorter postoperative length of stay (6.5+/-0.1 versus 9.2+/-0.3 days; P=0.003). GIK patients also showed a survival advantage over the initial 2 years after surgery (P=0.04) and decreased episodes of recurrent ischemia (5% versus 19%; P=0.01) and developed fewer recurrent wound infections (1% versus 10%, P=0.03). CONCLUSIONS: Tight glycemic control with GIK in diabetic CABG patients improves perioperative outcomes, enhances survival, and decreases the incidence of ischemic events and wound complications.
RCT Entities:
BACKGROUND: This study sought to determine whether tight glycemic control with a modified glucose-insulin-potassium (GIK) solution in diabetic coronary artery bypass graft (CABG) patients would improve perioperative outcomes. METHODS AND RESULTS: One hundred forty-one diabeticpatients undergoing CABG were prospectively randomized to tight glycemic control (serum glucose, 125 to 200 mg/dL) with GIK or standard therapy (serum glucose <250 mg/dL) using intermittent subcutaneous insulin beginning before anesthesia and continuing for 12 hours after surgery. GIK patients had lower serum glucose levels (138+/-4 versus 260+/-6 mg/dL; P<0.0001), a lower incidence of atrial fibrillation (16.6% versus 42%; P=0.0017), and a shorter postoperative length of stay (6.5+/-0.1 versus 9.2+/-0.3 days; P=0.003). GIK patients also showed a survival advantage over the initial 2 years after surgery (P=0.04) and decreased episodes of recurrent ischemia (5% versus 19%; P=0.01) and developed fewer recurrent wound infections (1% versus 10%, P=0.03). CONCLUSIONS: Tight glycemic control with GIK in diabetic CABGpatients improves perioperative outcomes, enhances survival, and decreases the incidence of ischemic events and wound complications.
Authors: Omid Fatemi; Eugene Yuriditsky; Costas Tsioufis; Demetrios Tsachris; Timothy Morgan; Jan Basile; Thomas Bigger; William Cushman; David Goff; Elsayed Z Soliman; Abraham Thomas; Vasilios Papademetriou Journal: Am J Cardiol Date: 2014-07-30 Impact factor: 2.778
Authors: Jeffrey B Boord; Mona Sharifi; Robert A Greevy; Marie R Griffin; Vivian K Lee; Ty A Webb; Michael E May; Lemuel R Waitman; Addison K May; Randolph A Miller Journal: J Am Med Inform Assoc Date: 2007-02-28 Impact factor: 4.497
Authors: William G Cotts; Edwin C McGee; Susan L Myers; David C Naftel; James B Young; James K Kirklin; Kathleen L Grady Journal: J Heart Lung Transplant Date: 2014-03-01 Impact factor: 10.247
Authors: Lily E Johnston; Jennifer L Kirby; Emily A Downs; Damien J LaPar; Ravi K Ghanta; Gorav Ailawadi; Benjamin D Kozower; Irving L Kron; Anthony L McCall; James M Isbell Journal: Ann Thorac Surg Date: 2016-08-25 Impact factor: 4.330